Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study
I'm PortAI, I can summarize articles.
Aethlon Medical Inc. announced preclinical data showing its Hemopurifier® device binds to extracellular vesicles in Long COVID patients, reducing inflammatory microRNAs. Published on bioRxiv, the study suggests the device removes elevated EVs in these patients. NanoString analyses identified seven microRNAs significantly reduced by the treatment. The findings support further investigation but are not yet in clinical trials. The news was generated by AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments